Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Executive Summary

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.


Related Content

US FDA Advertising Citations Remain Rare In 2018
How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice
Former US FDA Chief Counsels Offer Advice For Navigating Thorny First Amendment Conundrum
PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies
US FDA Wants To Know What Doctors Know About Abuse-Deterrent Opioids
PhRMA Seeks US FDA Rationale For Rx Drug Advertising Studies
Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
TV Drug Advertising Study Targets Those With Limited Or No Internet Use


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts